{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:19Z","timestamp":1793907319262,"version":"4.8.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bispecific antibodies (BsAbs) have expanded therapeutic options for patients with relapsed\/refractory B-cell lymphomas, yet their use has introduced a distinct spectrum of infectious complications that remain poorly characterized. In the largest cohort study to date, to our knowledge, we evaluated 109 patients treated with CD20\u00d7CD3 BsAbs between 2016 and 2024 to assess the incidence, characteristics, and risk factors of infections. Over a median follow-up of 28.4 months, 134 infectious episodes were identified, 61.2% of which were grade \u22653. The median time to infection onset was 6.6 months, with bacterial infections occurring earliest (5.9 months), followed by fungal (7.0 months) and viral infections (8.3 months). Among the microbiologically defined infections, viral infections were the most common (61.1%), with severe acute respiratory syndrome coronavirus 2 and cytomegalovirus (CMV) being the leading causes. Of the 109 patients, 68 (62.4%) experienced at least 1 infectious episode and 41 (37.6%) had grade \u22653 infections. The cumulative incidence of infection steadily increased over 24 months, reaching 76.4% at 24 months. The cumulative incidence of CMV infection steadily increased over the first 12 months. Neutropenia (absolute neutrophil count &amp;lt;1.0 \u00d7 109\/L) and hypogammaglobulinemia (immunoglobulin G level &amp;lt;400 mg\/dL) were independent risk factors for all-grade infection, whereas hypogammaglobulinemia was the sole independent risk factor for grade 3 to 5 infection. Early corticosteroid use was not associated with an increased infection risk. In summary, this study provides a temporal map of infection dynamics and highlights underrecognized complications, such as CMV reactivation. Risk-adapted therapeutic approaches and refined supportive care strategies are warranted for patients with B-cell lymphomas treated with BsAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017366","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:07:56Z","timestamp":1768496876000},"page":"2006-2015","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Infections after bispecific antibodies in B-cell lymphomas"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5763","authenticated-orcid":false,"given":"Dong Hyun","family":"Kim","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"},{"name":"2Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naryllae","family":"Lee","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-931X","authenticated-orcid":false,"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"},{"name":"4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-3548","authenticated-orcid":false,"given":"Hyeon Jae","family":"Jo","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Kyung","family":"Kang","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyoeng Gyun","family":"Choe","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Beom","family":"Park","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-0412","authenticated-orcid":false,"given":"Chan Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5553","authenticated-orcid":false,"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"},{"name":"4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-9467","authenticated-orcid":false,"given":"Nam Joong","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"8","key":"2026032014062055000_bib1","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"24","key":"2026032014062055000_bib2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2026032014062055000_bib3","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026032014062055000_bib4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2026032014062055000_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/ejh.14165","article-title":"Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea","volume":"112","author":"Kim","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026032014062055000_bib6","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"2026032014062055000_bib7","doi-asserted-by":"crossref","first-page":"20406207251349361","DOI":"10.1177\/20406207251349361","article-title":"Azacitidine followed by R-GDP in transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study","volume":"16","author":"Kim","year":"2025","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"2026032014062055000_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7 CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026032014062055000_bib9","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026032014062055000_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026032014062055000_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/infdis\/161.3.397","article-title":"From the immunocompromised host society: the design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel","volume":"161","author":"Pizzo","year":"1990","journal-title":"J Infect Dis"},{"key":"2026032014062055000_bib12","author":"Shah","year":"2022"},{"issue":"6","key":"2026032014062055000_bib13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2026032014062055000_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.19500","article-title":"Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome","volume":"205","author":"Kim","year":"2024","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026032014062055000_bib15","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/infdis\/jiz638","article-title":"Current understanding of cytomegalovirus reactivation in critical illness","volume":"221","author":"Imlay","year":"2020","journal-title":"J Infect Dis"},{"issue":"19","key":"2026032014062055000_bib16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2026032014062055000_bib17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2026032014062055000_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"7","key":"2026032014062055000_bib19","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2026032014062055000_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026032014062055000_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2026032014062055000_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026032014062055000_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"2026032014062055000_bib24","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026032014062055000_bib25","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jcyt.2017.07.012","article-title":"Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant","volume":"19","author":"Sutrave","year":"2017","journal-title":"Cytotherapy"},{"issue":"10","key":"2026032014062055000_bib26","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2026032014062055000_bib27","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1038\/s41598-024-64361-5","article-title":"Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"2026032014062055000_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3947\/ic.2024.0105","article-title":"Call for balancing the risks and benefits of immunotherapeutic agents for lymphoma during the COVID-19 pandemic","volume":"56","author":"Lee","year":"2024","journal-title":"Infect Chemother"},{"issue":"4","key":"2026032014062055000_bib29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3947\/ic.2017.49.4.255","article-title":"Cytomegalovirus infection after renal transplantation: occurrence, clinical features, and the cutoff for antigenemia in a university hospital in Brazil","volume":"49","author":"de Matos","year":"2017","journal-title":"Infect Chemother"},{"issue":"3","key":"2026032014062055000_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"issue":"2","key":"2026032014062055000_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.15971020","article-title":"Long-term infectious complications of kidney transplantation","volume":"17","author":"Agrawal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2026032014062055000_bib32","first-page":"521.e1-521.e7","article-title":"Cytomegalovirus infection post-allogeneic stem cell transplantation: experience from a country with high seropositivity","volume":"29","author":"Iftikhar","year":"2023","journal-title":"Transplant Cel Ther"},{"issue":"4","key":"2026032014062055000_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00277-011-1351-8","article-title":"Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus","volume":"91","author":"Liu","year":"2012","journal-title":"Ann Hematol"},{"key":"2026032014062055000_bib34","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S2152-2650(24)01942-6","article-title":"P-039 CMV reactivation during treatment with bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"24","author":"Jurgens","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"2026032014062055000_bib35","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3346\/jkms.2025.40.e86","article-title":"Incidence and characteristics of infectious complications in multiple myeloma patients treated with bispecific antibodies","volume":"40","author":"Park","year":"2025","journal-title":"J Korean Med Sci"},{"issue":"suppl 1","key":"2026032014062055000_bib36","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1182\/blood-2024-201519","article-title":"Cytomegalovirus reactivation in patients with multiple myeloma treated with teclistamab: risk factors and clinical impact","volume":"144","author":"Pei","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026032014062055000_bib37","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"25","key":"2026032014062055000_bib38","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2026032014062055000_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2026032014062055000_bib40","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"2026032014062055000_bib41","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026032014062055000_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cei.12600","article-title":"Immune deficiency: changing spectrum of pathogens","volume":"181","author":"Duraisingham","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2026032014062055000_bib43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematology Am Soc Hemotol Educ Program"},{"issue":"1","key":"2026032014062055000_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-024-01091-x","article-title":"Improving outcomes with anti-BCMA bispecific antibodies with attention to infection","volume":"14","author":"Yee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026032014062055000_bib45","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.clml.2020.12.026","article-title":"Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma","volume":"21","author":"Lancman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026032014062055000_bib46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2006\/2508496\/blooda_adv-2025-017366-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2006\/2508496\/blooda_adv-2025-017366-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:35Z","timestamp":1774029995000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/2006\/566017\/Infections-after-bispecific-antibodies-in-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017366","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,13]]}}}